350 руб
Журнал «Технологии живых систем» №3 за 2012 г.
Статья в номере:
Активаторы и ингибиторы ангиогенеза при опухолях
Ключевые слова: ангиогенез VEGF HIF противоопухолевая терапия
Авторы:
А.Ю. Назаренко, О.М. Кузнецова, Е.Ю. Руссо, У.Р. Мамедов, Т.Т. Березов
Аннотация:
В обзоре представлены новые данные об антиангиогенной противоопухолевой терапии. Для описанных в работе препаратов приведена структура, механизм их действия. Бевацизумаб, афлиберцепт, сунитиниб, сорафениб, эхиномицин, хетомин, 17-AAG, PX-12, ингибиторы mTOR рапамицина, циклофосфамид, паклитаксел, доксорубицин и винкристин находят широкое применение в терапии, но поскольку точный механизм их антиангиогенного действия до конца не известен, ведутся клинические исследования. В настоящее время также не отработаны стандартные маркеры, что является поводом к проведению исследований с целью поиска рецепторов, лигандов, морфологических признаков для назначения антиангиогенной терапии.
Страницы: 49-57
Список источников
  1. Folkman J. Tumor angiogenesis: therapeutic implications // New England Journal of Medicine. 1971. V. 285. P. 1182 - 1186.
  2. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules // Nature Reviews Clinical Oncology. 2009. V. 6. P. 507 - 518.
  3. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors // Nature Medicine. 2003. V. 9. P. 669 - 676.
  4. Ferrara N. Vascular endothelial growth factor // Arteriosclerosis Thrombosis and Vascular Biology. 2009. V. 29. P. 789 - 791.
  5. Cohen M.H., Gootenberg J., Keegan P. et al. FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer // The Oncologist. V. 12.№ 3. P. 356 - 361.
  6. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer // New Engl. J. Med. 2004. V. 350. P. 2335 - 2342.
  7. Van Meter M.E.M., Kim E.S. Bevacizumab: current updates in treatment // Current Opinion in Oncology. 2010. V. 22. № 6. P. 586 - 591.
  8. Hansel T.T., Kropshofer H., Singer T. et al. The safety and side effects of monoclonal antibodies // Nature Reviews Drug Discovery. 2010. V. 9. P. 325 - 338.
  9. Mailliez A., Baldini C., Van J.T., et al. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients // Brit. J. Cancer. 2010. V. 103. P. 772 - 775.
  10. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature // Ann. Oncol. 2008. V. 19. № 3. P. 577 - 582.
  11. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforations in patients with cancer treated by bevacizumab: a meta-analysis // The Lancet Oncology. 2009. V. 10. № 6. P. 559 - 568.
  12. Konnor J., Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity // Clinical Colorectal Cancer. 2004. V. 4. Suppl. 2. P. 81 - 85.
  13. Dupont J., Schwartz L., Koutcher J. et al. Phase I and pharmokinetic of VEGF Trap administered subcutaneously (sc) to patients (pt) with advanced solid malignancies // J. Clin. Oncol. 2004. V.22. № 15. P. 3009.
  14. Tew W.P., Colombo M., Ray-Coquard I. et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study.
  15. Staton C.A., Brown N.J., Reed M.W. Current status and future prospects for antiangiogenic therapies in cancer // Expert Opinion Drug Discovery. 2009. V. 4. P. 961 - 979.
  16. Gan H.K., Seruga B., Knox J.J. Sunitinib in solid tumors // Expert Opinion on Investigational Drugs. 2009. V. 18. P. 821 - 834.
  17. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma // J. Clin. Oncol. 2009. V. 27. № 22. P. 3584 - 3590.
  18. Demetri G.D., Huang X., Garret C.R. et al. Novel statistical analysis of long-term survival to account for crossover in phase III of sunitinib (SU) versus placebo (PL) in advanced GIST after imatinib (IM) failure (abstract) // J. Clin. Oncol.- ACSO Annual Meeting Proceedings. 2008. V. 26. P. 15S. 10524.
  19. Kulke M.H., Lenz H.-J., Meropol N.J. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors // J. Clin. Oncol. 2008. V. 26. № 20. P. 3403 - 3410.
  20. Sonpavde J., Periman P.O., Bernold D. et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy // Ann. Oncol. 2009. V. 21. № 2. P. 319 - 324.
  21. Biagi J.J., Oza A.M., ChalChal H.I. et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study // Ann. Oncol. 2010. doi: 10.1093/annonc/mdq357.
  22. Wilhelm S.M., Adnane L., Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling // Molecular Cancer Therapeutics. 2008. V. 7. P. 3129 - 3140.
  23. Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis // Cancer Res. 2004. V. 64. P. 7099 - 7109.
  24. Guevremont C., Jeldres C., Perrotte P. et al. Sorafenib in the management of metastatic renal cell carcinoma // Current Oncol. 2009. V. 16. Suppl. 1. P. 27 - 32.
  25. Kane R.C., Farrell A.T., Madabushi R. et al. Surafenib for the treatment of unresectable hepatocellular carcinoma // The Oncologist. 2009. V. 14. № 1. P. 95 - 100.
  26. Blumenschein G.R. Jr., Gatzemeier U., Fossella F. et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed of refractory, advanced non-small-cell lung cancer // J. Clin. Oncol. 2009. V. 27. № 26.  P. 4274 - 4280.
  27. Aragon-Ching J.B., Jain L., Gulley J.L. et al. Final analysis of phase II trial using sorafenib for metastatic castration-resistant prostate cancer // BJU International. 2009. V. 103. № 12. P. 1636 - 1640.
  28. Lichtenberger B.M., Tan P.K., Niederleithner H. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development // Cell. 2010. V. 140. № 2. P. 268 - 279.
  29. Frieze D.A. Current status of cetuximab for the treatment of patients with solid tumors // The Annals of Pharmacotherapy. 2006. V. 40. № 2. P. 241 - 250.
  30. Bonner J.A., Harari P.M., Giralt J. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival // The Lancet Oncology. 2010. V. 11. № 1. P. 21 - 28.
  31. Pirker R., Pereira J.R., Szczesna A. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial // The Lancet. 2009. V. 373. № 9674. P. 1525 - 1531.
  32. Gravalos C., Cassinello J., Garcia-Alfonso P. et al. Integration of panitumumab into the treatment of colorectal cancer // Critical Reviews in Oncology/Hematology. 2010. V. 74. № 1. P. 16 - 26.
  33. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer // J. Clin. Oncol. 2010. V. 28. № 7. P. 1254 - 1261.
  34. Weidemann A., Johnson R.S. Biology of HIF-α // Cell Death and Differentiation. 2008. V. 15. P.621 ? 627.
  35. Schofield C.J., Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases // Biochemical and Biophysical Research Communications. 2005. V. 38. P.617 ? 626.
  36. Talks K.L., Turley H., Gatter K.C. et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages // Am. J. Pathol. 2000. V. 157. P. 411 - 421.
  37. Giatromanolaki A., Sivridis E., Fiska A. et al. Hypoxia inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas // Applied Immunohistochemistry and Molecular Morphology. 2006. V. 14. P. 78 - 82.
  38. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions // FEBS J. 2007. V. 274. № 21. P.5533 - 5542.
  39. Gradishar W.G., Vogelzang N.J., Kilton L.J. et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study // Investigational New Drugs. 1995. V. 13. P. 171 - 174.
  40. Nickols N.G., Jacobs C.S., Farkas M.E. et al. Modulating hypoxia-inducible transcription by the HIF-1‑DNA interface // ACS Chemical Biology. 2007. V. 2. № 8. P. 561 - 571.
  41. Kung A.L., Wang S., Klco J.M. et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription // Nature Medicine. 2000. V. 6. P. 1335 - 1340.
  42. Kung A.L., Zabludoff S.D., France D.S. et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway // Cancer Cell. 2004. V. 6. P. 33 - 43.
  43. Cook K.M., Hilton S.T., Mecinovic J. et al.Epidi-
    thiodiketopiperazines block the interaction between hypoxia-inducible factor-1α (HIF-1α) and p300 by a zinc ejection mechanism // J. Biol. Chemistry. 2009. V. 284. P. 26831 - 26838.
  44. Bohonowych J.E., Gopal U., Isaacs J.S. HSP90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls // J. Oncol. 2010. doi: 10.1155/2010/412985
  45. Pick L., Kluger Y., Giltnane J.M. et al. High HSP90 expression is associated with decreased survival in breast cancer // Cancer Res. 2007. V. 67. P. 2932 - 2937.
  46. Solit D.B., Chiosis G. Development and application of HSP90 inhibitors // Drug Discovery Today. 2008. V. 13. P. 38 - 43.
  47. Taldone T., Gozman A., Maharaj R. et al. Targeting HSP90: small-molecule inhibitors and their clinical development // Current Opinion in Pharmacology. 2008. V. 8. P. 370 - 374.
  48. Karlenius T.C., Tonissen K.F. Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation // Cancers. 2010. V. 2. P. 209 - 232.
  49. Ramanathan R.K., Dragovich T., Richards D. et al. Results from phase Ib studies of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies // J. Clin. Oncol. ACSO Annual Meeting Proceedings. 2009. V. 27. № 15. P. 2571.
  50. Hixon M.L., Paccagnella L., Millham R. et al. Development of IGF-IR/PI3I/AKT/mTOR pathway // Reviews on Recent Clinical Trials. 2010. V. 5. № 3. P. 189 - 208.
  51. Fox S.B., Generali D.G., Harris A.L. Breast tumor angiogenesis // Breast Cancer Research. 2007. V.9.